These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 552863)

  • 1. Animal model for investigation of fluphenazine kinetics after administration of long-acting esters.
    Altamura AC; Whelpton R; Curry SH
    Biopharm Drug Dispos; 1979; 1(2):65-72. PubMed ID: 552863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluphenazine enanthate and fluphenazine decanoate: intramuscular injection and esterification as requirements for slow - release characteristics in dogs.
    Dreyfuss J; Shaw JM; Ross JJ
    J Pharm Sci; 1976 Sep; 65(9):1310-5. PubMed ID: 966144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man.
    Curry SH; Whelpton R; de Schepper PJ; Vranckx S; Schiff AA
    Br J Clin Pharmacol; 1979 Apr; 7(4):325-31. PubMed ID: 444352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.
    Viala A; Hou N; Ba B; Durand A; Dufour H; D'Agostino N; Berda C; Jørgensen A
    Psychopharmacology (Berl); 1984; 83(2):147-50. PubMed ID: 6146995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release and elimination of 14C-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs.
    Dreyfuss J; Ross JJ; Shaw JM; Miller I; Schreiber EC
    J Pharm Sci; 1976 Apr; 65(4):502-507. PubMed ID: 1271246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods for study of fluphenazine kinetics in man.
    Whelpton R; Curry SH
    J Pharm Pharmacol; 1976 Dec; 28(12):869-73. PubMed ID: 12260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of accumulation of fluphenazine enanthate and fluphenazine decanoate, long-acting neuroleptic drugs, after repeated administrations by means of their inhibitory effects on the discriminated avoidance response in rats.
    Kuribara H; Tadokoro S
    J Toxicol Sci; 1979 May; 4(2):87-98. PubMed ID: 501762
    [No Abstract]   [Full Text] [Related]  

  • 8. Excretion and biotransformation of the enanthate ester of fluphenazine- 14 C by the dog.
    Dreyfuss J; Ross JJ; Schreiber EC
    J Pharm Sci; 1971 Jun; 60(6):829-33. PubMed ID: 5128931
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma fluphenazine levels in patients receiving two doses of fluphenazine decanoate.
    Marder SR; Hubbard JW; Van Putten T; Hawes EM; McKay G; Mintz J; May PR; Midha KK
    Psychopharmacol Bull; 1986; 22(1):264-6. PubMed ID: 3726072
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
    Soni SD; Wiles D; Schiff AA; Bamrah JS
    Br J Psychiatry; 1988 Sep; 153():382-4. PubMed ID: 3250675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esters of 4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazieneethanol and related compounds as long-acting antipsychotic agents. Synthesis of the 1-adamantoate, the first crystalline base.
    Yale HL
    J Med Chem; 1977 Feb; 20(2):302-4. PubMed ID: 13218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depot fluphenazine enanthate and decanoate: comparative rates of release in dogs.
    Dreyfuss J; Ross JJ; Shaw JM; Miller I; Schreiber EC
    J Pharm Pharmacol; 1975 Oct; 27(10):791-2. PubMed ID: 241800
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics].
    Levron JC; Ropert R
    Encephale; 1987; 13(2):83-7. PubMed ID: 2885172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of the depot antipsychotics.
    Jann MW; Ereshefsky L; Saklad SR
    Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma-fluphenazine concentrations after injection of long-acting esters.
    Curry SH; Whelpton R; de Schepper PJ; Vranckx S; Schiff AA
    Lancet; 1978 Jun; 1(8075):1217-8. PubMed ID: 77990
    [No Abstract]   [Full Text] [Related]  

  • 16. Frequent questions about long-acting, injectable fluphenazine.
    Amdur MA
    IMJ Ill Med J; 1978 Mar; 153(3):193-6. PubMed ID: 24612
    [No Abstract]   [Full Text] [Related]  

  • 17. Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.
    Yamada K; Furukawa T
    Pharmacology; 1982; 24(3):147-55. PubMed ID: 7200248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological studies of long-acting phenothiazines with particular reference to fluphenazine decanoate (author's transl)].
    Chen PC
    Nihon Yakurigaku Zasshi; 1978 Oct; 74(7):871-83. PubMed ID: 570538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 1050 mg fluphenazine decanoate given intramuscularly over six days.
    Cheung HK; Yu EC
    Br Med J (Clin Res Ed); 1983 Mar; 286(6370):1016-7. PubMed ID: 6403175
    [No Abstract]   [Full Text] [Related]  

  • 20. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.
    Altamura AC; Curry SH; Montgomery S; Wiles DH
    Psychopharmacology (Berl); 1985; 87(1):30-3. PubMed ID: 3933035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.